The REACH trial is a prospective multicenter double-blind randomized placebo-controlled trial
with blinded end-point adjudication. Participants are randomized (1:1) to receive either
sodium aescinate or matching placebo (0.9% saline). The primary outcome is the absolute
volume of PHE evaluated based on brain CT image on day 14 after ICH.